SCHEMBL6922796

SCHEMBL6922796

CCCN(C)CC(=O)c1cc(C)n(-c2ccc(N)cc2)c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.46
ALDH1A1 P00352 4/20 0.46
MITF O75030 3/20 0.46
MAPT P10636 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HKDC1 Q2TB90 2/20 0.46
LMNA P02545 2/20 0.46
HTT P42858 3/20 0.45
RAB9A P51151 3/20 0.45
RECQL P46063 1/20 0.45
MGLL Q99685 1/20 0.45
NOTUM Q6P988 4/20 0.44
HPGD P15428 2/20 0.44
MAPK1 P28482 1/20 0.43
USP14 P54578 3/20 0.43
KDM4E B2RXH2 3/20 0.43
USP7 Q93009 2/20 0.43
POLB P06746 1/20 0.42
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6922486 0.90 ALDH1A1 (0.45) SMN1; SMN2ALDH1A1MITFMAPTMEN1
SCHEMBL6922806 0.90 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1MITFMAPTMEN1
SCHEMBL19749190 0.88 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1MITFMAPTMEN1
SCHEMBL17949747 0.88 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1MITFMAPTMEN1
SCHEMBL6923363 0.87 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1MITFMAPTMEN1
SCHEMBL6922881 0.87 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1MITFMAPTMEN1
SCHEMBL6923276 0.86 ALDH1A1 (0.50) SMN1; SMN2ALDH1A1MITFMAPTMEN1
SCHEMBL19749201 0.80 NOTUM (0.56) SMN1; SMN2ALDH1A1MITFMAPTMEN1
SCHEMBL19501341 0.80 NOTUM (0.58) SMN1; SMN2ALDH1A1MITFMAPTMEN1
SCHEMBL17949836 0.78 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1MITFMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528911-B1 COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY HARVARD COLLEGE (US) 2017-10-25 EP disclosed
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity THE ASSAY DEPOT, INC. 2016-07-28 US disclosed
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2015-11-26 US disclosed
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-18 US disclosed
WO-2014116228-A1 USP14 INHIBITORS FOR TREATING OR PREVENTING VIRAL INFECTIONS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-07-31 WO disclosed
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-02-21 US disclosed
WO-2011094545-A2 COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections USP14, USP1, USP13 SMN1; SMN2 1593/4885ALDH1A1 1697/4885MITF 3047/4885
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PSMG3, PSMB11, PSME3 SMN1; SMN2 307/4885ALDH1A1 4147/4885MITF 2237/4885
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity PSMG3, PSME3, PSMB11 SMN1; SMN2 307/4885ALDH1A1 4165/4885MITF 2257/4885
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation HSPA2, HSPBP1, HSPH1 SMN1; SMN2 544/4885ALDH1A1 2288/4885MITF 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.